Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

New Line of Single-Use Bags Meets Stringent Requirements of the Biopharmaceutical Industry

By BiotechDaily International staff writers
Posted on 19 Jun 2014
Image: Flexsafe represents a completely new generation of single-use bags that offer consistent cell growth as well as extraordinary robustness and flexibility (Photo courtesy of Sartorius Stedim Biotech).
Image: Flexsafe represents a completely new generation of single-use bags that offer consistent cell growth as well as extraordinary robustness and flexibility (Photo courtesy of Sartorius Stedim Biotech).
A major global supplier of laboratory products for the biopharmaceutical industry has begun marketing a new range of single-use bags in a multitude of sizes and shapes.

Sartorius Stedim Biotech (Goettingen, Germany) has announced the release of its line of Flexsafe single-use bags. Flexsafe, which is based on S80, a multilayer, proprietary polyethylene (PE) film, was developed in close collaboration with resin and film suppliers. The PE film is 400 micrometers thick, making Flexsafe one of the strongest and most flexible bags currently on the market.

Optimization of resin formulation, complete control of raw materials quality, the extrusion process, and bag assembly guarantee lot-to-lot consistent cell growth performance of even the most sensitive cell lines.

Flexsafe bags are safe and easy to manage, even for the most demanding applications such as liquid shipping and large-scale stirred bioreactors. Batch-to-batch consistent extractables and leachables profiles, which support drug manufacture throughout all processes from clinical development to commercial supply, guarantee that initial extractable and leachable qualification data will remain valid for every operation involving single-use Flexsafe bioprocess products.

"Flexsafe represents a completely new generation of single-use bags," said Stefan Schlack, senior vice president marketing and product management at Sartorius Stedim Biotech. "They offer our customers consistent cell growth as well as extraordinary robustness and flexibility. In addition a sustainable supply chain and consistent film throughout the entire manufacturing process is guaranteed. Every single one of these benefits sets a new benchmark. Being unique in all of them makes us very proud.”

Initially Sartorius Stedim Biotech is launching Flexsafe RM bags (1–200 liters) and small bags for validation purposes. Bags for single use bioreactors BIOSTAT STR (50–2,000 liters) and additional applications such as storage, mixing, shipping, freezing and thawing will be introduced over the coming months.

Related Links:

Sartorius Stedim Biotech 



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.